Trial Profile
Use of A4250, a Nonabsorbable Ileal Apical Sodium-Dependent Bile Acid Transporter Inhibitor for Nonalcoholic Steatohepatitis (BRAVO-1)
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase II
Latest Information Update: 16 Mar 2018
Price :
$35
*
At a glance
- Drugs Odevixibat (Primary)
- Indications Non-alcoholic fatty liver disease; Non-alcoholic steatohepatitis
- Focus Therapeutic Use
- Acronyms BRAVO-1
- 07 Mar 2018 New trial record